Sign In
Buy FHTX
$4.53
-0.210 (-4.43%)
At Close: Jul 31, 2026
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
07:30am, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript
08:56pm, Thursday, 30'th Oct 2025
Foghorn Therapeutics Inc. ( FHTX ) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs October 30, 2025 12:00 PM EDT Company Participants Karin Hellsvik - Chief of Staff t
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
07:30am, Thursday, 30'th Oct 2025
- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
07:00am, Thursday, 16'th Oct 2025
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT Foghorn to host a virtual
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
10:56am, Monday, 01'st Sep 2025
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
08:00am, Thursday, 28'th Aug 2025
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
01:01pm, Monday, 25'th Aug 2025
Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
10:56am, Friday, 08'th Aug 2025
Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
09:11am, Tuesday, 05'th Aug 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
07:00am, Tuesday, 05'th Aug 2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
07:00am, Thursday, 22'nd May 2025
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
09:25am, Wednesday, 14'th May 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
07:00am, Wednesday, 14'th May 2025
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show s
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
07:00am, Monday, 05'th May 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
